Advanced Therapy: How Indonesia Can Escape the Middle-Income Trap

Why It Matters

If Indonesia masters ATMP development, it can generate high‑value exports, reduce drug import dependence, and accelerate its climb out of the middle‑income trap. Success also positions the country as a precision‑medicine leader in Southeast Asia.

Key Takeaways

• Global ATMP pipelines exceed 4,000, 150 products approved
• Biological drugs now grow three times faster than small molecules
• Indonesia aims to shift regulation toward innovation driver
• ATMP success could transform health outcomes and export revenues

Pulse Analysis

Indonesia’s health system is under mounting pressure from rising chronic and complex diseases, a trend that threatens to stall its economic ascent. At the same time, the global biopharmaceutical sector is experiencing an unprecedented surge, with biologics now driving growth at three times the rate of traditional small‑molecule drugs. This convergence creates a strategic imperative for Indonesia to adopt advanced therapy medicinal products (ATMPs) such as gene, cell and RNA‑based treatments, which promise curative outcomes rather than mere symptom management.

The ATMP landscape is already maturing: by the end of 2025, more than 4,000 pipelines are in development worldwide, and about 150 products have secured marketing authorization. Recognizing this momentum, the head of BPOM positions the regulator not just as a watchdog but as an innovation catalyst, blending safety oversight with academic insight and national economic strategy. By streamlining approval pathways, fostering public‑private research collaborations, and incentivizing local manufacturing, Indonesia can build a domestic pipeline that reduces reliance on imported biologics and creates high‑skill jobs.

Economically, a thriving ATMP sector could be a game‑changer for Indonesia’s middle‑income trap. Exportable, high‑margin biologics would diversify the country’s trade basket, while homegrown therapies would lower healthcare spending and improve population health—both critical for sustainable growth. To realize this vision, Indonesia must invest in biotech talent, strengthen intellectual‑property frameworks, and align fiscal policies with global best practices. Success would not only elevate Indonesia’s standing in the global therapeutic arena but also provide a replicable model for other emerging economies seeking to leapfrog into high‑value, innovation‑driven growth.